Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug

Yasutaka Takagi[a], Tadashi Nakajima[a], Atsushi Shimazaki[a], Masaaki Kageyama[a], Takeshi Matsugi[a], Yasushi Matsumura[b], B'Ann T. Gabelt[c], Paul L. Kaufman[c], Hideaki Hara[a],*

[a]Glaucoma Group, Research and Development Center, Santen Pharmaceutical Co., Ltd, 8916-16, Takayama-cho, Ikoma 630-0101, Nara, Japan
[b]Fine Chemicals Group, Chemicals Company, Asahi Glass Co., Ltd, Tokyo, Japan
[c]Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA

Abstract

To evaluate the pharmacological characteristics of AFP-168 (tafluprost), a new prostaglandin (PG) $F_{2\alpha}$ derivative, we examined its receptor-binding affinities, intraocular pressure (IOP)-lowering effect, effects on aqueous humor dynamics, and stimulating effect on melanogenesis. The receptor-binding profile for AFP-172, a carboxylic acid of AFP-168, was determined by measuring muscle contractions in an organ bath, inhibition of platelet aggregation, and competitive binding of a radio-labelled ligand. For the IOP-measurement study, ocular normotensive and laser-induced ocular hypertensive cynomolgus monkeys were used, and IOP was measured using a pneumatonograph. For the studies of aqueous humor dynamics, IOP (Goldmann applanation tonometry), fluorophotometry, two-level constant pressure perfusion, and isotope dilution and accumulation techniques were used in ocular normotensive monkeys. The melanin contents in the medium and in the cell bodies of cultured B16-F0 melanoma cells were measured. The affinity for the FP receptor shown by AFP-172 (K_i: 0·4 nM) was 12 times that of PhXA85 (K_i: 4·7 nM), a carboxylic acid of latanoprost. A single application of AFP-168 at 0·0025% significantly lowered IOP in both ocular normotensive and hypertensive monkeys (3·1 and 11·8 mmHg, respectively, $p < 0·01$) and latanoprost at 0·005% significantly lowered IOP (2·1 mmHg, $p < 0·01$ and 9·5 mmHg, $p = 0·059$, respectively). Once daily instillation of AFP-168 at 0·001, 0·0025, or 0·005% for 5 days in normotensive monkeys significantly reduced IOP not only for a few hours, but also at the drug-trough time 24 hr after application. Latanoprost at 0·005% also reduced IOP, but not at the drug-trough time. AFP-168 decreased IOP mainly by increasing uveoscleral outflow by 65% ($p < 0·05$) and, as sometimes seen with other prostanoids, also increased total outflow facility (33% increase, $p < 0·05$). In cultured B16-F0 melanoma cells, AFP-172 (100 μM) did not stimulate melanogenesis, but PhXA85 (100 μM) did. These findings indicate that AFP-168 has a high affinity for the prostanoid FP receptor, has potent IOP-lowering effects in both ocular normotensive and hypertensive monkeys that exceed those of latanoprost, and has less stimulating effect on melanogenesis in melanoma cells.
© 2004 Elsevier Ltd. All rights reserved.

1. Introduction

AFP-168 (tafluprost), 1-methylethyl (5Z)-7-[(1R,2R, 3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy -1-butenyl]-3,5-dihydroxycyclopentyl]-5-heptenoate and AFP-172, a carboxylic acid of AFP-168, are newly synthesized prostaglandin (PG) $F_{2\alpha}$ analogues (Fig. 1). AFP-168 is under development as an ocular hypotensive drug in the USA, Europe, and Japan. It is a pro-drug ester that facilitates corneal penetration and allows delivery of the active carboxylic acid form (AFP-172) to the aqueous humor, a similar situation to that seen with $PGF_{2\alpha}$-isopropyl ester and other ocular hypotensive derivatives of $PGF_{2\alpha}$, such as latanoprost.

Glaucoma is a major cause of blindness worldwide, and many ocular hypotensive drugs are in existence. For over 20 years, β-blockers such as timolol were the first-line therapy.

* Corresponding author. Dr Hideaki Hara, Glaucoma Group, Research and Development Center, Santen Pharmaceutical Co., Ltd, 8916-16, Takayama-cho, Ikoma 630-0101, Nara, Japan.
E-mail address: hideaki.hara@santen.co.jp (H. Hara).

R = isopropyl : AFP-168
R = H : AFP-172

Fig. 1. Chemical structures of AFP-168 and AFP-172.

Then, after the discovery of the intraocular pressure (IOP)-lowering effects of PGs (Camras and Bito, 1981), several PG-derivatives such as isopropyl unoprostone (Taniguchi et al., 1996), latanoprost (Stjernschantz et al., 1995; Camras et al., 1996), bimatoprost (Woodward et al., 2001), and travoprost (Sharif et al., 1999; Hellberg et al., 2001) were launched into the market as anti-glaucoma drugs. The IOP-lowering effect of latanoprost has been found to be greater than that of timolol in a number of clinical comparative studies (Alm, 1995; Mishima et al., 1996; Watson et al., 1996; Alm et al., 2000). Recently, because of its potent IOP-lowering effects and fewer general side effects, latanoprost has been used as first-line therapy in many countries, including the USA and Japan.

Prostanoid FP-receptor agonists have potent IOP-lowering efficacy, and effectively no general side effects. However, PG-related ocular hypotensive drugs do have local side effects, such as pigmentation of the iris (Wistrand et al., 1997; Yamamoto and Kitazawa, 1997; Sherwood and Brandt, 2001; Netland et al., 2001), palpebra or/and periocular skin (Wand et al., 2001), and abnormal eyelash growth (trichiasis) (Johnstone, 1997). Furthermore, the existing PG-related ocular hypotensive drugs, including latanoprost, do not produce satisfactory IOP control in all patients. We therefore tried to find a new candidate as an ocular hypotensive drug that exceeds latanoprost in terms of IOP-lowering efficacy, and has weaker local side effects.

In this study, in a comparison with latanoprost, we examined the binding affinity of AFP-172 for recombinant human prostanoid FP receptors, the binding selectivity of AFP-172, the IOP-lowering effects of AFP-168 in ocular normotensive and laser-induced ocular hypertensive monkeys, the effects of AFP-168 on aqueous humor dynamics in ocular normotensive monkeys, and the effects of AFP-172 on melanogenesis in cultured B16-F0 melanoma cells.

2. Materials and methods

2.1. Materials

AFP-168 and AFP-172 were synthesized at the laboratories of Asahi Glass Co. Ltd (Tokyo, Japan). Latanoprost,

unoprostone isopropyl, and $PGF_{2\alpha}$-isopropyl ester were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Latanoprost ophthalmic solution (Xalatan®) was purchased from Pharmacia K. K. (Tokyo, Japan), pilocarpine hydrochloride from Sigma-Aldrich Corp. (St Louis, MO, USA), and [3H] $PGF_{2\alpha}$ (200 μCi/μl) from Amersham Biosciences Corp. (Piscataway, NJ, USA). [125I] and [131I] were obtained from PerkinElmer Life Sciences, Inc. (Boston, MA, USA). Timolol-gel forming ophthalmic solution (Timoptol-XE®) was a product of Santen Pharmaceutical Co. Ltd (Osaka, Japan). PhXA85 and unoprostone (carboxylic acids of latanoprost and unoprostone isopropyl, respectively) were prepared at the laboratories of Santen Pharmaceutical Co. Ltd. Because latanoprost, unoprostone isopropyl, and AFP-168 are pro-drug esters, and each is converted to its respective acid by the esterase in the cornea, the carboxylic acid forms were used in vitro, while the ester forms were used in vivo.

2.2. Receptor-binding assays

2.2.1. Prostanoid FP receptor

For the prostanoid FP receptor-binding study, we used a clonal cell line that stably expresses the recombinant human prostanoid FP receptor (Abramovitz et al., 1994). The radioligand-binding assay was performed according to the methods of Abramovitz et al. (1994) and Graves et al. (1995). In this conventional filtration assay, membranes expressing the receptor are incubated with a fixed concentration of the radioligand and increasing concentrations of the test compounds. After reaching equilibrium, the radioligand bound to the membranes (bound) is separated from the unbound (free) radioligand by filtration through glass-fiber filters. The amount of bound radioactivity is determined by liquid scintillation spectrometry (LS5000TD; Beckman Coulter Inc., Fullerton, CA, USA), and the amount of bound radioactivity is plotted as a function of the logarithm of the concentration of the competing test compound. Increasing concentrations of the competing test compound decrease the binding of the radioligand according to the laws of mass action, and the affinity (IC_{50}) of the test compound for the receptor can be determined by non-linear regression analysis according to

$$B = \text{non-specific binding}$$

$$+ \frac{(\text{total binding} - \text{non-specific binding})}{1 + 10^{\log[C] - \log(IC_{50})}}$$

where B equals the amount of radioligand-binding at a given concentration of test compound [C], total binding equals the amount of radioligand-binding in the absence of test compound, and non-specific binding equals the residual amount of radioligand-binding after complete displacement of specific binding by a saturating concentration of the test compound.

2.2.2. Prostanoid DP, EP_1, EP_2, EP_3, IP, and TP receptors

Binding affinity for the prostanoid DP receptor was determined by measuring the inhibition of the adenosine diphosphate (ADP)-induced aggregation of rabbit platelets. Platelet-rich plasma was prepared from freshly obtained rabbit blood, and platelet aggregation was induced by 10 μM ADP (Eglen and Whiting, 1989). Binding affinities for the prostanoid EP_1, EP_2, and EP_3 receptors were determined by measuring muscle contractions in an organ bath. The muscles, which were attached to an isometric transducer, were maintained at 37°C in aerated (95% O_2, 5% CO_2) Krebs–Hensleit solution. For the prostanoid EP_1 receptor, contraction of the guinea pig ileum was induced by 1 μM AFP-172 (Eglen and Whiting, 1989), and the contraction induced by AFP-172 was expressed as a percentage of the maximal response to 10 μM acetylcholine. For the prostanoid EP_2 receptor, contraction of the guinea pig trachea was induced by 1 μM carbachol, then inhibited by 1 μM AFP-172. For the prostanoid EP_3 receptor, twitch contractions of the guinea pig vas deferens were induced by electrical stimulation (1 min interval, 5 sec trains of pulses at maximal voltage; pulse width, 1 msec; frequency, 5 Hz), then inhibited by AFP-172 (Savage et al., 1993). The binding studies for prostanoid IP and TP receptors were performed by a contract facility (Cerep, France) with standard binding procedures.

2.2.3. Other receptors and transporters

The binding studies for other receptors and transporters listed in Table 3 were performed by another contract facility (Daiichikagaku Pure Chemicals Co. Ltd, Toukaimura, Japan) with standard binding procedures.

2.3. IOP measurement

For the studies on ocular normotensive monkeys, 10 adult male cynomolgus monkeys, each weighing 4·7–7·4 kg (Keari Co. Ltd, Osaka, Japan), were used for the single-application experiment, and another 10 adult monkeys, each weighing 4·5–8·1 kg (Animal Care Co. Ltd, Tokyo, Japan), were used for a repeated-application study. Only animals with normal eyes (in terms of anterior chamber, angles, IOP, ocular media, and optic nerve heads) were included in these studies. For the ocular hypertensive monkey study, 12 adult cynomolgus monkeys, each weighing 5·2–8·1 kg (Keari Co. Ltd, Osaka, Japan), were used. Elevated IOP was produced in the monkeys according to a previous report (Lee et al., 1985), with a minor modification. Briefly, ocular hypertension was induced in the left eye by photocoagulating the trabecular meshwork using an argon laser (Ultima 2000; Coherent-Japan, Tokyo, Japan), applying 150 burns around 360 degrees twice with a 1-week interval. The present study was carried out more than 4 weeks after the last photocoagulation. If the IOP in the photocoagulated eye was not 5 mmHg greater than that in the non-photocoagulated fellow eye, the animal was not used for this study.

Before we measured IOP, all monkeys were trained for restraint in a monkey chair (CL-4535; Primate Products, Miami, FL, USA) and for measurements of IOP. For IOP measurements, the monkey was kept in a sitting position in the monkey chair, and the IOP was measured with a pneumatonograph (Model Classic 30R; Soran Ophthalmic, Jacksonville, FL, USA) without any general anesthesia or sedation. For corneal anesthesia, 0·4% oxybuprocain solution (Santen Pharmaceutical Co. Ltd, Osaka, Japan) was topically applied prior to IOP measurement. Drugs (20 μl) were applied to one eye in each monkey, with the contralateral eye remaining untreated. In the normotensive monkey study (single application), IOP was measured just before and at 2, 4, 6, 8, and 24 hr after drug application. In the normotensive monkey study (repeated application), IOP was measured just before and at 4, 6, 8, and 24 hr on days 1, 3, and 5 of the drug-application protocol. In the ocular hypertensive monkey study, drugs (20 μl) were applied to the left eye with elevated IOP in each monkey, at 9–10 a.m. IOP was measured just before and at 2, 4, 6, 8, 12, and 24 hr after drug application. A masked observer (F. N.) measured IOP in all experiments. A crossover design was applied to these studies; each animal contributed to all groups.

Prior to aqueous humor dynamics studies, IOP responses to AFP-168 (4×5 μl of 0·005%), timolol (2 μl containing 5 μg timolol) and $PGF_{2\alpha}$-isopropyl ester (2×5 μl of 0·02%) were confirmed in monkeys anaesthetized with ketamine HCl (10 mg kg^{-1}, i.m.) using a minified Goldmann applanation tonometer (Kaufman and Davis, 1980).

2.4. Aqueous humor dynamics assays

For the aqueous humor dynamics study, we used a total of 28 adult male and female cynomolgus monkeys, each weighing 2·5–6·0 kg (the majority from Covance Inc., Madison, WI, USA; two from the Coulston Foundation, Almagordo, NM, USA; one born at the University of Wisconsin, Madison, WI, USA). Aqueous humor formation (AHF) was measured in eight monkeys (i.m. ketamine anesthesia, 10 mg kg^{-1} initial supplemented by 5 mg kg^{-1} as needed) by fluorophotometry (Gabelt et al., 1994); total outflow facility was measured in the same eight monkeys plus four additional ones (i.m. ketamine (10 mg kg^{-1}) followed by i.v. pentobarbital (15 mg kg^{-1} initial, supplemented with 5–10 mg kg^{-1} as needed)) using two-level constant pressure perfusion (Bárány, 1964; Gabelt et al., 1991); uveoscleral outflow and trabecular outflow were measured in the same 12 monkeys by means of isotope accumulation (Sperber and Bill, 1984; Gabelt et al., 2003) prior to outflow facility measurements on the same day. Only animals with normal eyes (in terms of anterior chamber, angles, IOP, ocular media, and optic nerve heads) were used. In these studies, 4×5 μl of 0·005% AFP-168 was applied once daily for 3–5 days; 5 μg timolol (2 μl of timolol-gel forming solution diluted with saline) was applied once daily for 3 days; 2×5 μl of 0·02%

$PGF_{2\alpha}$-isopropyl ester was applied twice daily for 4 or 5 days to eight monkeys different from the previous 12; 100 μg/10 μl pilocarpine HCl was applied intracamerally to yet another group of eight different monkeys.

The rate of AHF was determined in ketamine anaesthetized monkeys using a Coherent scanning ocular fluorophotometer (Fluorotron Master, Palo Alto, CA, USA). Fluorescein (10% fluorescite for injection, Alcon Laboratories, Inc., Fort Worth, TX, USA) was administered topically on the afternoon preceding the fluorophotometry experiments (usually five 2 μl drops of 5% solution diluted with 0·1 M sodium phosphate buffer, pH 7·4) 5 min after one drop of 0·5% proparacaine hydrochloride (Bausch and Lomb Pharmaceuticals, Inc., Tampa, FL, USA). This kept the corneal fluorescein concentration at 200 ng ml^{-1} or more during the measurement period. On the experimental day, scans were recorded in each eye every hour for 5 hr.

Isotopic determination of AHF was performed in pentobarbital anaesthetized monkeys beginning 3 hr after the last dose of AFP-168 (fourth or fifth dose of once daily treatments) or $PGF_{2\alpha}$-isopropyl ester (seventh or ninth dose of twice daily treatments) by circulating [^{125}I] or [^{131}I]monkey albumin through the anterior chamber and measuring the dilution of label with newly formed aqueous (by counting a portion of the circuit every 5 min over a 2 hr period in a well detector/multichannel analyzer system, (ASA-100 NaI multichannel analyzer, Genie-2000 Spectroscopy Software, Canberra Industries, Inc., Meriden, CT, USA). Flow through the trabecular meshwork was determined by taking blood samples every 10 min from a femoral artery and counting them in a gamma counter (COBRA model D5003, Packard Instrument Co., Downers Grove, IL, USA). Uveoscleral outflow was calculated as the difference between AHF and trabecular outflow.

Total outflow facility was determined in pentobarbital anaesthetized monkeys by two-level constant pressure perfusion of the anterior chamber with Bárány's mock aqueous humor, correcting for the internal resistance of the perfusion apparatus as appropriate (Bárány, 1964). For AFP-168 and $PGF_{2\alpha}$-isopropyl ester studies, total outflow facility was determined for approximately 45 min at the conclusion of isotope studies and were completed within hours 5–6 after the fourth or fifth dose of once daily treatments with AFP-168 or after the seventh or ninth dose of twice daily treatments with $PGF_{2\alpha}$-isopropyl ester. For pilocarpine, the anterior chambers of both eyes were cannulated with a branched needle (with one branch connected to a reservoir and the other to a pressure transducer). Baseline facility measurements were taken for 35–45 min. Following baseline measurements, a bolus injection of 10 μl containing 100 μg pilocarpine HCl was made into the inflow tubing of one eye, Bárány's into the opposite eye tubing. Following a 5-min wash in period with the reservoirs elevated, cold air was blown on the corneas to mix the anterior chamber contents by convection. Post-drug outflow facility was then determined for another

35–45 min. Facility was calculated by successive averaging (Bárány, 1964).

2.5. Melanogenesis assay

B16-F0 melanoma cells were purchased from Dainippon Pharmaceutical Co. Ltd (Osaka, Japan). Melanin contents were measured as in previous reports (Siegrist and Eberle, 1986; Kosano et al., 1995). Briefly, fourth- or fifth-passage B16-F0 melanoma cells (ATCC No. CRL6322; 5×10^3 cells/well) were seeded in a 24-well plate (Asahi Techno Glass Corp., Funabashi, Japan) in culture medium (Dulbecco's modified Eagles medium containing 10% fetal bovine serum and 50 μg ml^{-1} gentamicin). Starting the day after seeding, the cells were cultured for 4 days in culture medium with or without drug (AFP-172 or PhXA85). The culture medium was collected, and the cells dissolved in lysis buffer (0·1N NaOH solution containing 10% Triton X-100) with 10-sec sonication. The melanin content of the medium and cell lysates was measured by absorbance at 490 and 415 nm, respectively.

2.6. Statistical analysis

The following statistical analyses were performed. For the IOP measurement study, the maximal reduction in IOP was used for statistical analysis. A Student's *t*-test was carried out following an *F*-test. Dunnett's test and the Tukey–Kramer test were carried out following a one-way analysis of variance. For the aqueous humor dynamics study, a two-tailed paired *t*-test was carried out on the values obtained for treated/control ratios. $p < 0.05$ was taken as statistically significant.

3. Results

3.1. Receptor-binding assays

3.1.1. Prostanoid FP receptor

Prior to the FP binding study, we confirmed the expression of prostanoid FP receptors in the clonal cells. Immunofluorescence microscopy using an anti-FP receptor antibody, examination of the accumulation of inositol phosphates induced by fluprostenol, and radioligand-binding competition curve analysis of $PGF_{2\alpha}$ to [^{3}H]$PGF_{2\alpha}$ revealed that the clonal cell line used in this study did indeed express human FP receptors (data not shown). AFP-172 showed a high affinity for the human prostanoid FP receptor, with an EC_{50} of 0·53 nM. The affinity of AFP-172 was 12 times that of PhXA85 and 1700 times that of unoprostone (Table 1). AFP-172 produced full displacement of specific [^{3}H]$PGF_{2\alpha}$ binding and competed in a manner consistent with a simple bimolecular reaction (Hill slope ~1), as did PhXA85 and unoprostone.

Table 1
Fifty percent inhibition concentration (IC_{50}) and affinities of AFP-172, PhXA85, and unoprostone for the human prostanoid FP receptor

Compounds	IC_{50} (nM)	K_i (nM)	Potency ratio (K_i value of AFP-172 = 1)
AFP-172	0·53 ± 0·18	0·4	1
PhXA85	6·3 ± 1·3	4·7	12
Unoprostone	900 ± 55	680	1700

Affinity for the prostanoid FP receptor was determined by competitive binding to radiolabelled prostaglandin $F_{2\alpha}$. The 50% inhibition concentration (IC_{50}) and K_i values were calculated from the following equations:

$$B = \text{non-specific binding} + \frac{(\text{total binding} - \text{non-specific binding})}{1 + 10^{\log[C] - \log(IC_{50})}};$$

$$K_i = \frac{IC_{50}}{1 + [\text{radioligand}]/K_d};$$

Data represent the mean ± S.E.M. from far to five experiments; B; amount of radioligand binding; C; concentration of test compound; K_i; equilibrium inhibition constant; K_d; equilibrium dissociation constant.

3.1.2. Prostanoid DP, EP₁, EP₂, EP₃, IP, and TP receptors

The inhibitory or stimulatory effects of AFP-172 on the binding or pharmacological responses of prostanoid receptors are shown in Table 2. AFP-172 at 1 μM did not show evidence of inhibitory or stimulatory effects on any receptor binding, except that of the prostanoid EP_3 receptor. The IC_{50} of AFP-172 for the prostanoid EP_3 receptor was 67 nM, and the binding affinity of AFP-172 was 126 times weaker for this receptor than for the prostanoid FP receptor (see Tables 1 and 2). PGD_2 (DP), PGE_2 (EP_1), butaprost (EP_2), 17-phenyl trinol-PGE_2 (EP_3), iloprost (IP) and U44069 (TP) were used as positive controls in each experiment.

3.1.3. Other receptors and transporters

As shown in Table 3, the inhibitory effects of AFP-172 at 1 μM on a variety of receptor and transporter bindings were all less than 15%.

Table 2
Receptor-binding affinities or functional activities of AFP-172 to prostanoid DP, EP₁, EP₂, EP₃, IP, and TP receptors

Prostanoid receptors	Assays	EC_{50} or IC_{50} (nM)
DP	Inhibition of ADP-induced aggregation in rabbit platelets	>1000
EP₁	Contraction in guinea pig ileum	>1000
EP₂	Inhibition of carbachol-induced contraction in guinea pig trachea muscle	>1000
EP₃	Inhibition of electrical stimulation-induced contraction in guinea pig vas deferens	67
IP	Inhibition of [³H]iloprost binding in human platelets	>1000
TP	Inhibition of [³H]SQ29548 binding in human platelet	>1000

Data are averaged from two or four experiments.

Table 3
Inhibitory effects of AFP-172 on various receptors and transporters

Receptors/ transporters	Radioligand/assay	Inhibition (%) (1 μM AFP-172)
Adenosine A₁	[³H]dipropylcyclopentylxanthine	<15
Adenosine A₂ₐ	[³H]CGS21680	<15
Adrenergic α₁ (non-selective)	[³H]Prazosin	<15
Adrenergic α₂ (non-selective)	[³H]RX821002	<15
Adrenergic β₁	[³H]CGP12177	<15
Angiotensin AT₁	[¹²⁵I]Angiotensin II	<15
Benzodiazepine	[³H]Flunitrazepam	<15
Bradykinin B₂	[³H]Bradykinin	<15
Cannabinoid CB₁	[³H]CP55940	<15
Cannabinoid CB₂	[³H]WIN55212-2	<15
Cholecystokinin CCK_A	[³H]L-364718	<15
Dopamine D₁	[³H]SCH23390	<15
Dopamine D₂	[³H]Spiperone	<15
Dopamine transporter	[³H]WIN35428	<15
Endothelin ET_A	[¹²⁵I]Endothelin-1	<15
γ-Aminobutyric acid (GABA)_A	[³H]Flunitrazepam	<15
Glutamate (non-selective)	[³H]Glutamic acid	<15
Histamine H₁	[³H]Pyrilamine	<15
Melanocortin MC₄	[³H]4-Norleucine, 7-D-phenylalanine-α-melanocyte stimulating hormone	<15
Muscarinic (non-selective)	[³H]Quinuclidinyl benzilate	<15
Neurokinin NK₁	[³H]Substance P	<15
Neuropeptide Y₁	[¹²⁵I]Peptide YY	<15
Neuropeptide Y₂	[¹²⁵I]Peptide YY	<15
Norepinephrine transporter	[³H]Nisoxetine	<15
Nicotinic Ni	[³H]Epibatidine	<15
Opiate (non-selective)	[³H]Naloxone	<15
Orphanin ORL₁	[³H]Nociceptin	<15
Serotonin 5HT₁ (non-selective)	[³H]Serotonin	<15
Serotonin transporter	[³H]Imipramine	<15
Sigma (σ)	[³H]1,3,-Di-o-tolylguanidine	<15
Vasopressin V₁ᵦ	[³H]Arg-Vasopressin	<15
Vasopressin V₂	[³H]Arg-Vasopressin	<15

Data are averaged from two experiments.

3.2. Effects of a single application of AFP-168 on intraocular pressure in conscious normotensive monkeys

Fig. 2 shows the maximum IOP reductions of a single application of either AFP-168 or latanoprost in conscious ocular normotensive monkeys. The maximal IOP reductions with AFP-168 (0·00002–0·0025%) were dose-dependent, and significance was reached at doses of 0·0005 and 0·0025%. The maximal IOP reduction seen with AFP-168

Fig. 2. Effects of a single application of AFP-168 or latanoprost (maximal reduction in intraocular pressure (IOP)) in conscious ocular normotensive monkeys. Data represent the mean ± s.e.m. for 12 animals. **$p < 0.01$ vs. vehicle (Tukey–Kramer test).

at 0.0025% was over 3 mmHg, greater than that induced by latanoprost at 0.005% (which was approximately 2 mmHg, statistically significant compared to that in the vehicle-treated eye). The potency of AFP-168 at 0.0005% was almost equal to that of latanoprost at 0.005%.

3.3. Effects of repeated applications of AFP-168 on intraocular pressure in conscious normotensive monkeys

Fig. 3 shows time–course data for the effects of repeated applications of AFP-168 or latanoprost on IOP in ocular normotensive monkeys. Mean IOP values at the pre-treatment time in all groups were within a narrow range (21.5–22.1 mmHg), and there was no statistically significant difference among the groups. All doses of AFP-168 reduced IOP at 4, 6, and 8 hr after their application on days 1, 3, and 5. Latanoprost at 0.005% caused significant IOP reductions at 4, 6, and 8 hr after its application on days 1, 3, and 5. While latanoprost did not reduce IOP at the trough time-point (24 hr after its application; i.e. 0 hr on days 2–6

in Fig. 3), AFP-168 at 0.0025 and 0.005% did significantly reduce IOP at each trough time-point from 0 hr on day 3 (24 hr on day 2) through 0 hr on day 6 (24 hr on day 5). Even with AFP-168 at 0.001%, an IOP reduction at the trough time-point was observed after 0 hr on day 3 (24 hr on day 2), and this effect was significant on and after 0 hr on day 4 (24 hr on day 3). Fig. 4 shows the daily maximal IOP reductions induced by AFP-168 and latanoprost. The daily maximal reductions induced by all doses of AFP-168 and latanoprost increased after day 1, but statistically significant increases vs. day 1 were observed only with AFP-168 at 0.0025 and 0.005%. The maximal IOP reductions achieved with AFP-168 at 0.0025 (mean ± s.e.m.: 4.7 ± 0.2 and 5.0 ± 0.2 mmHg at day 3 and 5, respectively, $n = 10$) and 0.005% (6.1 ± 0.2 and 5.8 ± 0.3 mmHg at days 3 and 5, respectively, $n = 10$) were greater than that achieved with latanoprost at 0.005% (4.2 ± 0.3 and 4.2 ± 0.4 mmHg at day 3 and 5, respectively, $n = 10$).

3.4. Effects of a single application of AFP-168 on intraocular pressure in conscious laser-induced ocular hypertensive monkeys

Fig. 5 shows the maximal IOP reductions induced by applications of AFP-168 and latanoprost in laser-induced ocular hypertensive monkeys. The mean IOP values at the pre-treatment time in all groups were in the range 35.8–38.7 mmHg, and there was no statistically significant difference among the groups. AFP-168 (0.00002–0.0025%) induced a dose-dependent IOP reduction, the maximal reduction at 0.0025 and 0.005% (11.8 and 10.5 mmHg, respectively,) being statistically significant compared to that in the vehicle-treated eye (6.2 mmHg). The effect of AFP-168 on laser-induced ocular hypertension seemed to peak at 0.0025%, then almost plateau. The maximal IOP reduction (9.5 mmHg) seen after application of latanoprost tended to be greater than that in the vehicle-treated eye, but with borderline significance ($p = 0.057$)·


Fig. 3. Effects of once daily application of AFP-168 or latanoprost on intraocular pressure (IOP) in conscious ocular normotensive monkeys. IOP change was calculated from time 0 on day 1. Drugs were instilled at 10:30 a.m. on each day from day 1 to day 5. Data represent the mean ± s.e.m. for 10 animals. *$p < 0.05$, **$p < 0.01$ vs. vehicle (Dunnett's multiple-range test).

Fig. 4. Effects of a once daily application of AFP-168 or latanoprost (maximal reduction in intraocular pressure (IOP)) in conscious ocular normotensive monkeys. Drugs were instilled at 10:30 a.m. on each day from day 1 to day 5. Data represent the mean ± S.E.M. for 10 animals. $*p < 0.05$ vs. day 1 (Dunnett's multiple-range test).

The reduced IOP had returned almost to the initial value at 24 hr after drug application.

3.5. Effect of AFP-168 on aqueous humor dynamics in anaesthetized ocular normotensive monkeys

Table 4 shows the effects of AFP-168, timolol-gel forming solution, $PGF_{2\alpha}$-isopropyl ester, and pilocarpine on each parameter relating to aqueous humor dynamics in ocular normotensive monkeys.

By fluorophotometry, once daily application of AFP-168 at 0·005% for 3 days did not affect AHF. On the other hand, once daily application of timolol for 3 days significantly decreased AHF by 23%.

According to the isotope perfusion data, once daily application of AFP-168 at 0·005% for 4 or 5 days significantly decreased the flow to blood (FTB) by 22%, and significantly increased both AHF by 14% and


Fig. 5. Effects of AFP-168 and latanoprost (maximal reduction in intraocular pressure (IOP)) in conscious laser-induced ocular hypertensive monkeys. Data represent the mean ± S.E.M. for 10 or 11 animals. $*p < 0.05$, $**p < 0.01$ vs. vehicle (Dunnett's multiple-range test).

uveoscleral outflow (Fu) by 65%. In this experiment, the FTB value is assumed to represent outflow through the trabecular meshwork (conventional outflow).

Twice daily application of $PGF_{2\alpha}$-isopropyl ester at 0·02% for 4 or 5 days did not affect AHF, but significantly decreased FTB by 59% and tended to increase Fu (although not significantly due to variability in the data).

Once daily application of AFP-168 at 0·005% for 4 or 5 days significantly increased total outflow facility by 33% compared to contralateral control eyes, but twice daily application of $PGF_{2\alpha}$-isopropyl ester at 0·02% for 4 or 5 days did not. However, the control eye values in AFP-168 animals tended to be lower than those of the control eyes for $PGF_{2\alpha}$-isopropyl ester and pilocarpine; the absolute facility values for AFP-168-treated and $PGF_{2\alpha}$-isopropyl ester-treated eyes were almost exactly the same. Intracameral application of pilocarpine significantly increased total outflow facility by 184%.

3.6. Effect of AFP-168 on melanogenesis in B16-F0 melanoma cells

Fig. 6 shows the effects of AFP-168 and latanoprost on melanogenesis in cultured B16-F0 melanoma cells. In these cells, α-melanocyte stimulating hormone increased the melanin content in both the culture medium and cell bodies (data not shown). AFP-172 at 1–100 μM and PhXA85 at 1 and 10 μM did not increase the melanin content in either the culture medium or cell bodies. PhXA85 at 100 μM significantly increased the melanin content above that seen with vehicle.

4. Discussion

AFP-172, a carboxylic acid of AFP-168, showed a potent affinity for the prostanoid FP receptor, and its affinity was greater than that of either PhXA85, a carboxylic acid of latanoprost, or unoprostone. The binding affinity of AFP-172 was 126 times higher for the prostanoid FP receptor than for EP_3 receptor. On the other hand, AFP-172 showed no or less affinity for other prostanoid receptors (DP, EP_1, EP_2, IP and TP) and other receptors and transporters. AFP-172 also contracted the isolated cat iris sphincter muscle and its efficacy was greater than that of PhXA85 (Nakajima et al., 2003). These findings indicate that the binding profile of AFP-172, like that of PhXA85, is that of a selective agonist for the prostanoid FP receptor (Stjernschantz et al., 1995). Since the structural characteristics of AFP-168 and AFP-172 involve two fluorine atoms in position 15 in the β-chain of the prostaglandin structure, its fluorine atoms may bestow a more potent affinity for the prostanoid FP receptor than that exhibited by other PG derivatives.

We demonstrated ocular hypotensive effects of AFP-168 in ocular normotensive and laser-induced ocular hypertensive monkeys. A single application of AFP-168

Table 4
Effects of AFP-168 on aqueous humor dynamics in anaesthetized ocular normotensive monkeys

Experiments/treatments (n)	Control (contralateral eye)	Treated eye	Ratio of treated/control
Fluorophotometry for aqueous humor formation (AHF, $\mu l\ min^{-1}$)			
Baseline (8)	1.49 ± 0.14	1.43 ± 0.12	0.97 ± 0.03
AFP-168 (8)	1.73 ± 0.13	1.88 ± 0.12	1.10 ± 0.04
Baseline (8)	1.55 ± 0.14	1.64 ± 0.17	1.06 ± 0.05
Timolol-gel (8)	1.39 ± 0.15	1.06 ± 0.10	$0.77 \pm 0.02^{**}$
Isotope perfusion for AHF ($\mu l\ min^{-1}$), flow to blood (FTB, $\mu l\ min^{-1}$), and uveoscleral outflow (Fu, $\mu l\ min^{-1}$)			
AHF AFP-168 (12)	1.54 ± 0.12	1.73 ± 0.15	$1.14 \pm 0.06^{*}$
FTB AFP-168 (12)	0.78 ± 0.16	0.61 ± 0.14	$0.78 \pm 0.06^{**}$
Fu AFP-168 (10)	0.92 ± 0.17	1.22 ± 0.14	$1.65 \pm 0.24^{*}$
AHF PGF$_{2\alpha}$-ie (8)	1.45 ± 0.17	1.54 ± 0.19	1.11 ± 0.14
FTB PGF$_{2\alpha}$-ie (8)	0.43 ± 0.12	0.14 ± 0.03	$0.41 \pm 0.08^{**}$
Fu PGF$_{2\alpha}$-ie (8)	1.01 ± 0.22	1.40 ± 0.20	2.31 ± 0.99
Two-level constant pressure perfusion for total outflow facility ($\mu l\ min^{-1}\ mmHg^{-1}$)			
AFP-168 (12)	0.45 ± 0.08	0.57 ± 0.11	$1.33 \pm 0.13^{*}$
PGF$_{2\alpha}$-ie (8)	0.60 ± 0.10	0.58 ± 0.09	1.15 ± 0.23
Pilocarpine (8)	0.83 ± 0.16	2.23 ± 0.40	$2.84 \pm 0.33^{**}$

PGF$_{2\alpha}$-ie: prostaglandin F$_{2\alpha}$-isopropyl ester; Aqueous humor formation (AHF) was calculated from the dilution of fluorescein or ^{125}I-albumin in the anterior chamber. Total outflow facility for AFP-168 and PGF$_{2\alpha}$-ie was measured at the conclusion of isotope studies by two-level constant pressure perfusion. Flow through the trabecular meshwork was determined from the radioactivity in the blood. Uveoscleral outflow (Fu) was taken as the difference between aqueous formation and trabecular outflow; Data represent the mean $\pm$ S.E.M. For ratio values, $^{*}p < 0.05$, $^{**}p < 0.01$ for difference from 1.0 (two-tailed paired t-test).

induced a dose-dependent IOP reduction in conscious ocular normotensive monkeys. The peak time for the IOP reduction induced by AFP-168 was 8 hr after its application, similar to latanoprost. The duration of the IOP reduction seen with AFP-168 was greater than that seen with latanoprost. Once daily applications of AFP-168 led to progressive increases in the daily maximal IOP reduction and in the IOP reduction at the trough time-point (just before the next application). These effects at the trough time-point were not observed with latanoprost. These results indicate that the IOP-lowering effect of AFP-168 is stronger and more continuous than that of latanoprost in the monkey. AFP-168 also induced an IOP reduction in laser-induced ocular hypertensive monkeys, in which the IOP reductions induced by AFP-168 at 0.0025 and 0.005% were statistically significant, and greater than that of latanoprost at 0.005%. Taken together, the above results suggest that the IOP-lowering effect of AFP-168 might be greater than that of latanoprost in the clinic as well.

The mechanism underlying the IOP-lowering effect of AFP-168 was investigated in ocular normotensive monkeys. The methods used in this study were validated by their ability to detect the effects of positive controls, such as timolol, PGF$_{2\alpha}$-isopropyl ester and pilocarpine. AFP-168 decreased the flow to blood (FTB, conventional outflow) and increased the uveoscleral outflow. The effect of AFP-168 on AHF was similar by the different methods: increases of 10% by fluorophotometry (not significant) and 14% by isotope perfusion (significant). Compared to the increase in uveoscleral outflow, this increase in AHF is relatively small. Therefore, AFP-168 may affect AHF slightly, as do the other PGF$_{2\alpha}$ analogues (Lindén and Alm, 1997; Brubaker

et al., 2001). AFP-168 also decreased FTB, presumably due to rerouting of flow to the uveoscleral pathway. Among the four ways to reduce IOP (decrease in AHF, increase in conventional outflow facility (increase in FTB at any constant pressure), increase in Fu, or decrease in episcleral venus pressure (EVP)), AFP-168 increased Fu and total outflow facility, but did not decrease AHF or increase FTB. Thus, the primary mechanism underlying the IOP-reducing effect of AFP-168 is via an increase in uveoscleral outflow, as with other PG derivatives (Stjernschantz et al., 1995). Simultaneously measured vehicle-treated contralateral eyes are the best controls for drugs not expected to act systemically, so the effect, whether on the uveoscleral or the trabecular outflow pathways, is likely to be real. In any case, the effect on facility, although significant by this


Fig. 6. Effects of AFP-172 and PhXA85 on melanogenesis in B16-F0 melanoma cells. Drugs were added to the culture medium for 4 days. Data represent the mean $\pm$ S.E.M. from four experiments. $^{*}p < 0.05$ vs. vehicle (Dunnett's multiple-range test).

measure, is still very small compared to that of pilocarpine. Also, the total outflow facility increase seen with AFP-168 in the current study is not different than the total outflow facility effect sometimes seen with $PGF_{2\alpha}$-isopropyl ester in other studies which subsequently demonstrated that the effect was not on trabecular outflow facility (Gabelt and Kaufman, 1990). The increase in total outflow facility might be due to an increase in uveoscleral facility. There is still controversy over whether or not Fu may become more pressure sensitive with PGs (Toris and Pederson, 1987; Gabelt and Kaufman, 1990; Becker and Neufeld, 2002; Bill et al., 2003). Techniques to unequivocally measure uveoscleral facility are needed to determine whether this is responsible for the increases in total outflow facility that are sometimes found.

PhXA85 increased melanogenesis in cultured B16-F0 melanoma cells, but AFP-172 did not. Although the concentration of PhXA85 needed to achieve such an effect was extraordinarily high, it may indicate that latanoprost can induce melanogenesis. Application of latanoprost for several months causes alterations in iris or periocular skin colour through the induction of melanogenesis (Wistrand et al., 1997; Yamamoto and Kitazawa, 1997; Wand et al., 2001). Therefore, the incidence of iris or periocular colour change may be expected to be lower with AFP-168 than with latanoprost. Further studies will be needed to clarify the difference.

In conclusion, AFP-172, a carboxylic acid of AFP-168, exhibited a high and selective binding affinity for the prostanoid FP receptor, and did not affect melanogenesis in cultured B16-F0 melanoma cells. Furthermore, the maximal IOP reduction achieved with AFP-168 at 0·0025% was greater than with latanoprost at 0·005% in both normotensive and ocular hypertensive monkeys. In its pharmacological characteristics, AFP-168 may be superior to latanoprost: potent IOP-reducing efficacy and weak melanogenetic side effect.

Acknowledgements

References

Abramovitz, M., Boie, Y., Nguyen, T., Rushmore, T.H., Bayne, M.A., Metters, K.M., Slipetz, D.M., Grygorczyk, R., 1994. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269, 2632–2636.

Alm, A., 1995. Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure. Adv. Prostaglandin Thromboxane Leukot. Res. 23, 527–532.

Alm, A., Camras, C.B., Watson, P.G., 2000. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv. Ophthalmol. 41, S105–S110.

Bárány, E.H., 1964. Simultaneous measurements of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest. Ophthalmol. 3, 135–143.

Becker, B., Neufeld, A.H., 2002. Pressure dependence of uveoscleral outflow. J. Glaucoma 11, 464(letter to the editor).

Bill, A., Kaufman, P.L., Yablonski, M.E., Camras, C.B., Becker, B., Neufeld, A.H., 2003. Some thoughts on the pressure dependence of uveoscleral flow. J. Glaucoma 12, 88–94. (letter to the editors).

Brubaker, R.F., Schoff, E.O., Nau, C.B., Carpenter, S.P., Chen, K., Vandenburgh, A.M., 2001. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am. J. Ophthalmol. 131, 19–24.

Camras, C.B., Bito, L.Z., 1981. Reduction of intraocular pressure in normal and glaucomatous primate (*Aotus trivirgatus*) eyes by topically applied prostaglandin $F_{2\alpha}$. Curr. Eye Res. 1, 205–209.

Camras, C.B., Wax, M.B., Ritch, R., Weinreb, R., Robin, A.L., Higginbotham, E.J., Lustgarten, J., Stewart, W.C., Sherwood, M., Krupin, T., Wilensky, J., Cioffi, G.A., Katz, L.J., Schumer, R.A., Kaufman, P.L., Minckler, D., Zimmerman, T., Stjernschantz, J., 1996. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 103, 138–147.

Eglen, R.M., Whiting, R.L., 1989. Characterization of the prostanoid receptor profile of enprostil and isomersin smooth muscle and platelets in vitro. Br. J. Pharmacol. 98, 1335–1343.

Gabelt, B.T., Crawford, K., Kaufman, P.L., 1991. Outflow facility and its response to pilocarpine decline in aging rhesus monkeys. Arch. Ophthalmol. 109, 879–882.

Gabelt, B.T., Gottanka, J., Lütjen-Drecoll, E., Kaufman, P.L., 2003. Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest. Ophthalmol. Vis. Sci. 44, 2118–2125.

Gabelt, B.T., Kaufman, P.L., 1990. The effect of prostaglandin $F_{2\alpha}$ on trabecular outflow facility in cynomolgus monkeys. Exp. Eye Res. 51, 87–91.

Gabelt, B.T., Robinson, J.C., Hubbard, W.C., Peterson, C.M., Debink, N., Wadhwa, A., Kaufman, P.L., 1994. Apraclonidine and brimonidine effects of anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. Exp. Eye Res. 59, 633–644.

Graves, P.E., Pierce, K.L., Bailey, T.J., Rueda, B.R., Gil, D.W., Woodward, D.F., Yool, A.J., Hoyer, P.B., Regan, J.W., 1995. Cloning of a receptor for prostaglandin $F_{2\alpha}$ from the ovine corpus luteum. Endocrinology 136, 3430–3436.

Hellberg, M.R., Sallee, V.L., McLaughlin, M.A., Sharif, N.A., Desantis, L., Dean, T.R., Zinke, P.W., 2001. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocular. Pharmacol. Ther. 17, 421–432.

Johnstone, M.A., 1997. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am. J. Ophthalmol. 124, 544–547.

Lee, P.-Y., Podos, S.M., Howard-Williams, J.R., Severin, C.H., Rose, A.D., Siegel, M.J., 1985. Pharmacological testing in the laser-induced monkey glaucoma model. Curr. Eye Res. 4, 775–781.

Lindén, C., Alm, A., 1997. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. Acta Ophthalmol. Scand. 75, 412–415.

Kaufman, P.L., Davis, G.E., 1980. 'Minified' Goldmann applanating prism for tonometry in monkeys and humans. Arch. Ophthalmol. 98, 542–546.

Kosano, H., Setogawa, T., Kobayashi, K., Nishigori, H., 1995. Pyrroloquinoline quinone (PQQ) inhibits the expression of tyrosinase mRNA by α-melanocyte stimulating hormone in murine B16 melanoma cells. Life Sci. 56, 1707–1713.

Mishima, H.K., Masuda, K., Kitazawa, Y., Azuma, I., Araie, M., 1996. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: A 12-week study. Arch. Ophthalmol. 114, 929–932.

Nakajima, T., Matsugi, T., Goto, W., Kageyama, M., Mori, N., Matsumura, Y., Hara, H., 2003. New fluoroprostaglandin $F_{2\alpha}$ derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol. Pharm. Bull. 26, 1691–1695.

Netland, P.A., Landry, T., Sullivan, E.K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M.V.W., Robertson, S.M., Davis, A.A., 2001. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132, 472–484.

Savage, M.A., Moummi, C., Karabatsos, P.J., Lanthorn, T.H., 1993. SC-46275: a potent and highly selective agonist at the EP3 receptor. Prostaglandins Leukot. Essent. Fatty Acids 49, 939–943.

Sharif, N.A., Davis, T.L., Williams, G.W., 1999. [^{3}H]AL-5848 ([^{3}H]9β-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharmac. Pharmacol. 51, 685–694.

Sherwood, M., Brandt, J., 2001. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45, S361–S368.

Siegrist, W., Eberle, A.N., 1986. In situ melanin assay for MSH using mouse B16 melanoma cells in culture. Anal. Biochem. 159, 191–197.

Sperber, G.O., Bill, A., 1984. A method for near-continuous determination of aqueous humor flow; effects of anaesthetics, temperature and indomethacin. Exp. Eye Res. 39, 435–453.

Stjernschantz, J., Selén, G., Sjöquist, B., Resul, B., 1995. Preclinical pharmacology of latanoprost, a phenyl-substituted $PGF_{2\alpha}$ analogue. Adv. Prostaglandin Thromboxane Leuket. Res. 23, 513–518.

Taniguchi, T., Haque, M.S., Sugiyama, K., Hori, N., Kitazawa, Y., 1996. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J. Ocul. Pharmacol. Ther. 12, 489–498.

Toris, C.B., Pederson, J.E., 1987. Aqueous humor dynamics in experimental iridocyclitis. Invest. Ophthalmol. Vis. Sci. 28, 477–481.

Wand, M., Ritch, R., Isbey, E.K.J., Zimmerman, T.J., 2001. Latanoprost and periocular skin color changes. Arch. Ophthalmol. 119, 614–615.

Watson, P., Stjernschantz, J., Beck, L., Blackmore, M., Coakes, R., Reynolds, P., Davey, C., Hickman-Casey, J., Elkington, A., Luff, A., Green, F., Valenzuela, F., Longstaff, S., Currie, Z., Mills, B., Chatterjee, A., Murray, S., Nagasubramanian, S., Potts, M., 1996. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103, 126–137.

Wistrand, P.J., Stjernschantz, J., Olsson, K., 1997. The incidence and time–course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. 41, S129–S138.

Woodward, D.F., Krauss, A.H., Chen, J., Lai, R.K., Spada, C.S., Burk, R.M., Andrews, S.W., Shi, L., Liang, Y., Kedzie, K.M., Chen, R., Gil, D.W., Kharlamb, A., Archeampong, A., Ling, J., Madhu, C., Ni, J., Rix, P., Usansky, J., Usansky, H., Weber, A., Welty, D., Yang, W., Tang-Liu, D.D., Garst, M.E., Brar, B., Wheeler, L.A., Kaplan, L.J., 2001. The pharmacology of bimatoprost (Lumigan). Surv. Ophthalmol. 47, S337–S345.

Yamamoto, T., Kitazawa, Y., 1997. Iris-color change developed after topical isopropyl unoprostone treatment. J. Glaucoma 6, 430–432.